Overview

This trial is active, not recruiting.

Conditions chronic kidney disease, end-stage renal disease
Phase phase 0
Sponsor China Medical University Hospital
Start date August 2010
Trial size 80 participants
Trial identifier NCT01250626, DMR99-IRB-139

Summary

Inulin's usefulness as a diagnostic agent is based on the method of its elimination from the body. Inulin is biologically inert, unbound by plasma proteins, freely filtered at the glomerulus, and is neither reabsorbed, metabolized nor secreted by the kidneys. It is excreted almost entirely by glomerular filtration. Inulin clearance is considered to be identical to glomerular filtration rate (GFR).

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model case-only
Time perspective prospective
Arm
Pediatric OPD, age < 18 y/o.

Eligibility Criteria

Male or female participants up to 18 years old.

1. Main inclusion criteria: Pediatric OPD, age < 18 y/o. 2. Main exclusion criteria: Acute renal failure, edema, muscular dystrophy, pleural effusion, ascites, malnutrition, neurogenic bladder, heart failure and ketoacidosis. And taken cimetidine or trimethoprim, and accepted renal replacement therapy.

Trial information was received from ClinicalTrials.gov and was last updated in November 2010.
Information provided to ClinicalTrials.gov by China Medical University Hospital.